Press Releases

GelStat Migraine to Be Placed in Mail Order Catalogs Distributed to Ten Million Households in April of 2007

Download PDF

ST. PAUL, MN -- (MARKET WIRE) -- 02/26/07 -- GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is announcing that its patented migraine treatment "GelStat(TM)Migrane" has been selected to be included in two mail order catalogs that will be sent to approximately ten million households in April of 2007.

Jim LaFlamme the Company's Chairman of the Board of Directors, stated, "This is one of the most significant events in the Company's history and clearly demonstrates GelStat's new strategy to increase brand recognition and revenue streams while minimizing monthly expenses." Mr. LaFlamme also commented, "I'd like to personally thank Tom DeSantis and the whole U.S. Marketing team for their tireless efforts with Catalog Solutions to see this opportunity come to fruition."

This event is a direct result of the Company's agreement with Catalog Solutions, which was announced, on 12/21/06 and provides GelStat with an enormous opportunity to introduce its safe and effective migraine treatment to millions of consumers. One of the catalogs is AmeriMark -- Healthy Living that is mailed out to 90 million households each year and is including GelStat(TM)Migrane in its Spring 2007 catalog, which will be mailed to 8-10 millions customers. It has a product mix of aids for better living, health, beauty, and vitamin supplement products. Its customer demographic is Middle America, ages 35-75 and 70% women, which is the ideal fit for GelStat(TM)Migrane.

Additionally, the product is going to be placed in the Miracle of Aloe catalog, which is a health and beauty catalog that specializes in creams, lotions, vitamins and supplements. This catalog has a similar demographic to Amerimark and will be circulating to over two million households when it is distributed in April of 2007.


GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

Click the following links to view supporting information on the effectiveness of GelStat Migraine:

Initial Clinical Trial of GelStat Migraine Shows it to be Effective for 83 Percent of those with Moderate to Severe Migraine

GelStat is Effective in Relieving Migraine Pain in a Double-Blind, Placebo-Controlled study

2 Minute Video Demonstrating the Product and its Successful Treatment of a Migraine Headache

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat(TM) Arthritis is the second available product to utilize GelStat's patent-pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat(TM) Sinus" and "GelStat(TM) Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit

Safe Harbor Statement under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

Redwood Consultants, LLC